At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 253 enrolled
Drug / intervention
CF101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating CF101 and Placebo for Rheumatoid Arthritis. Completed, enrolled 253 participants across 26 sites in 6 countries.
Detailed Summary
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Czechia, Israel, Poland, Serbia, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartFeb 2008
Primary CompletionMar 2009
Study CompletionApr 2009
TodayJul 2026
First PostedNov 12, 2007
Enrollment StartFeb 1, 2008
Primary CompletionMar 1, 2009
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 18.6 years ago
Interventions
CF101drug
orally q12h
Placebodrug
orally q12h